Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03069027
Other study ID # 3-2-17
Secondary ID
Status Completed
Phase N/A
First received February 19, 2017
Last updated December 23, 2017
Start date August 15, 2016
Est. completion date July 1, 2017

Study information

Verified date December 2017
Source Al Jedaani Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Emergence agitation following general anaesthesia may lead to serious complications like self-extubation or removal of catheters, which can lead to hypoxia, aspiration pneumonia, bleeding or reoperation. Nose surgery is associated with a higher incidence of emergence agitation. The investigators planned to evaluate the efficacy of external nasal nerve block in prevention of postoperative agitation following external nasal surgeries under general anesthesia(GA).


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date July 1, 2017
Est. primary completion date April 15, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria:

- 110 adult patients of ASA physical status I and II,

- Age 20-60 years,

- Scheduled for elective external nasal surgeries in which nasal packing on each side was used postoperatively for 24 hours.

Exclusion Criteria:

1. History of uncontrolled hypertension,

2. Ischemic or valvular heart disease,

3. Use of MAO inhibitors or adrenergic blocking drugs,

4. Cognitive impairment,

5. Patients taking antipsychotics,

6. Renal insufficiency or liver dysfunction

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
External nasal nerve block
Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
Drug:
saline adrenaline

Xylocaine, adrenaline


Locations

Country Name City State
Saudi Arabia Al Jedaani group of hospitals Jeddah Meccah

Sponsors (1)

Lead Sponsor Collaborator
Al Jedaani Hospital

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type Measure Description Time frame Safety issue
Primary postoperative agitation Assessment done using Richmond agitation- sedation scale (RASS) Emergence is defined as the time interval from discontinuation of anesthesia to 5 min after extubation.
Primary Quality of recovery Quality of recovery 24 hours postoperative
Secondary dose of fentanyl Fentanyl boluses were given in response to changes in hemodynamics (more than 15% increases in MAP and HR than the baseline values taken after induction by 5 minutes) intraoperative period in minutes
Secondary morphine dose in PACU equivalent morphine dose in PACU (calculated using opioid:morphine equivalents of 100 µg i.v. fentanyl to 10 mg i.v. morphine; 75- 100 mg IV pethidine to 10 mg i.v. morphine one hour in PACU
Secondary Nausea and vomiting in PACU Four-point nausea and vomiting scale (0=no nausea; 1=mild nausea; 2=severe nausea requiring antiemetics; and 3=retching, vomiting, or both) was also evaluated one hour in PACU
Secondary Extubation time Up to 15 after discontinuation of anesthesia
Secondary Surgical time intraoperative duration of surgery in minutes up to 3 hours
Secondary first verbal response time period from discontinuation of anesthesia 'time zero' to 1st verbal response in minutes up to 15 minutes
Secondary complication of nasal block including local anesthetic systemic toxicity, vascular injury, intravascular injection of local anesthetic, and local hematoma. From injection to 24 hours postoperative